{
    "Patient": {
        "Name": "Sara Bradshaw",
        "DOB": "1991-10-14",
        "Sex": "Male",
        "Caseno": "8570",
        "Diagnosis": "Invasive ductal carcinoma",
        "Physician": "Dr. Donald Burns"
    },
    "specimen information": {
        "primary_tumor_site": "Breast",
        "specimen_site": "Lymph nodes (axillary",
        "specimen_ID": "4123",
        "CollectedDate": "2023-05-03",
        "ReceivedDate": "2023-05-05",
        "Pathological Diagnosis": "Left breast, central, 12:00, suspicious mass, 12-gauge core needle biopsy: Infiltrating moderately-differentiated mammary carcinoma, grade 2, Nottingham score 6 (architectural grade 3, nuclear grade 2, mitotic figures 1).",
        "Dissection Information": "Molecular testing of this specimen was performed after harvesting of targeted tissues with an approved manual microdissection technique. Candidate slides were examined under a microscope and areas containing tumor cells (and separately normal cells, when necessary for testing) were circled. A laboratory technician harvested targeted tissues for extraction from the marked areas using a dissection microscope."
    },
    "Results with Therapy association": [
        {
            "Biomarker": "ER",
            "Method": "IHC",
            "Analyte": "protein",
            "Result": "Positive | 3+, 100%",
            "Therapy association": [
                "BENEFIT",
                "abemaciclib",
                "palbociclib",
                "ribociclib",
                "endocrine",
                "therapy",
                "everolimus"
            ],
            "Biomarker_level": "level 2"
        },
        {
            "Biomarker": "PR",
            "Method": "IHC",
            "Analyte": "protein",
            "Result": "Positive | 2+, 95%",
            "Therapy association": [
                "BENEFIT",
                "abemaciclib",
                "palbociclib",
                "ribociclib",
                "endocrine therapy"
            ],
            "Biomarker_level": "level 2"
        },
        {
            "Biomarker": "TMB",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Result": "10 m/Mb Low",
            "Therapy association": [
                "BENEFIT",
                "pembrolizumab"
            ],
            "Biomarker_level": "level 2"
        },
        {
            "Biomarker": "ERBB2",
            "Method": "IHC",
            "Analyte": "Protien",
            "Result": "Negative | 0",
            "Therapy association": [
                "LACK OF BENEFT",
                "trastuzumab",
                "ado-trastuzumab emtansine",
                "pertuzumab",
                "fam-trastuzumab deruxtecan-nxki",
                "lapatinib",
                "neratinib",
                "tucatinib"
            ],
            "Biomarker_level": "level 1"
        }
    ],
    "Relevant Biomarkers": [
        {
            "BioMarker": "HBB",
            "Method": "Seq",
            "Analyte": "RNA-Tumor",
            "Result": "Mutation not detected"
        },
        {
            "BioMarker": "ALK",
            "Method": "Seq",
            "Analyte": "RNA-Tumor",
            "Result": "Mutation not detected"
        },
        {
            "BioMarker": "Mismatch repair status",
            "Method": "IHC",
            "Analyte": "Protien",
            "Result": "Negative| 2+, 100%"
        }
    ],
    "Genomic Signatures": [
        {
            "BioMarker": "Microsatellite instability",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Result": "Low"
        },
        {
            "BioMarker": "Tumor mutational burden",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Result": "10 mutations/Mb Low"
        },
        {
            "BioMarker": "Genomic loss of heterozygosity (LOH)",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Result": "Low - 11% of tested genomic segments exhibit LOH"
        }
    ],
    "Genes Tested with Pathogenic Alterations": [
        {
            "Gene": "TEK",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Benign",
            "Protien Alteration": "p.T367N",
            "Exon": 6,
            "DNA Alteration": "c.1100C>A",
            "Allele Frequency %": "3.09"
        },
        {
            "Gene": "TEK",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Likely Pathogenic",
            "Protien Alteration": "p.S34X",
            "Exon": 19,
            "DNA Alteration": "1",
            "Allele Frequency %": "21.84"
        },
        {
            "Gene": "AKT1",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Likely Pathogenic",
            "Protien Alteration": "p.H362R",
            "Exon": 20,
            "DNA Alteration": "c.1085A>G",
            "Allele Frequency %": "27.9"
        },
        {
            "Gene": "IDH2",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Likely Benign",
            "Protien Alteration": "p.Y303H",
            "Exon": 15,
            "DNA Alteration": "1",
            "Allele Frequency %": "4.71"
        },
        {
            "Gene": "PDGFRB",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Likely Benign",
            "Protien Alteration": "p.G466E",
            "Exon": 6,
            "DNA Alteration": "c.1790T>A",
            "Allele Frequency %": "16.37"
        }
    ],
    "Gene variants of unknown significance": [
        {
            "Gene": "BTK",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Variant of uncertain significance",
            "Protien Alteration": "p.F332V",
            "Exon": 16,
            "DNA Alteration": "G",
            "Allele Frequency %": "24.44"
        },
        {
            "Gene": "CSF3R",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Variant of uncertain significance",
            "Protien Alteration": "p.G12V",
            "Exon": 14,
            "DNA Alteration": "c.183A>G",
            "Allele Frequency %": "7.43"
        },
        {
            "Gene": "ARID2",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Variant of uncertain significance",
            "Protien Alteration": "p.S1982Rfs*22",
            "Exon": 20,
            "DNA Alteration": "c.5946delT",
            "Allele Frequency %": "3.6"
        },
        {
            "Gene": "SIX1",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Variant of uncertain significance",
            "Protien Alteration": "p.F1888L",
            "Exon": 4,
            "DNA Alteration": "c.5662T>C",
            "Allele Frequency %": "7.32"
        },
        {
            "Gene": "TOP2A",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Variant of uncertain significance",
            "Protien Alteration": "p.*143Qext*31",
            "Exon": 6,
            "DNA Alteration": "c.427T>C",
            "Allele Frequency %": "3.72"
        }
    ],
    "Immunohistochemistry results": [
        {
            "Biomarker": "PD-L1(SP142)",
            "Result": "Positive| 3+, 79%"
        },
        {
            "Biomarker": "PMS2",
            "Result": "Negative| 1+, 50%"
        },
        {
            "Biomarker": "MSH2",
            "Result": "Negative| 2+, 18%"
        }
    ],
    "Genes Tested with indeterminate results": [
        "PDGFRA",
        "SIX1",
        "TEK",
        "FOXL2"
    ],
    "Chemotherapy clinical trials": [
        {
            "Drug class": "Anti hormonal therapy",
            "Biomarker": "ER",
            "Method": "IHC",
            "Analyte": "protein",
            "Investigational agents": [
                "anastrazole",
                "letrozole",
                "exemestane",
                "fulvestrant",
                "tamoxifen",
                "goserelin",
                "leuprolide"
            ]
        },
        {
            "Drug class": "Anti hormonal therapy",
            "Biomarker": "PR",
            "Method": "IHC",
            "Analyte": "protein",
            "Investigational agents": [
                "anastrazole",
                "letrozole",
                "exemestane",
                "fulvestrant",
                "tamoxifen",
                "goserelin",
                "leuprolide"
            ]
        },
        {
            "Drug class": "Anti inflammatory agents",
            "Biomarker": "PIK3CA",
            "Method": "NGS",
            "Analyte": "DNA tumor",
            "Investigational agents": [
                "aspirin"
            ]
        }
    ],
    "Targeted therapy clinical trials": [
        {
            "Drug class": "Akt inhibitors",
            "Biomarker": "ARID1A",
            "Method": "NGS",
            "Analyte": "DNA tumor",
            "Investigational agents": [
                "AZD5363",
                "MK-2206",
                "ipataserib"
            ]
        },
        {
            "Drug class": "immunomodulatory agents",
            "Biomarker": "TMB",
            "Method": "NGS",
            "Analyte": "DNA tumor",
            "Investigational agents": [
                "avelumab",
                "atezolizumab",
                "durvalumab",
                "ipilimumab",
                "nivolumab",
                "pembrolizumab"
            ]
        },
        {
            "Drug class": "PARP inhibitors",
            "Biomarker": "NBN",
            "Method": "NGS",
            "Analyte": "DNA tumor",
            "Investigational agents": [
                "BGB-290",
                "BMN-673",
                "olaparib",
                "rucaparib",
                "talazoparib"
            ]
        },
        {
            "Drug class": "Akt/mTor inhibitors",
            "Biomarker": "PIK3CA",
            "Method": "NGS",
            "Analyte": "DNA tumor",
            "Investigational agents": [
                "AZD5363",
                "BYL719",
                "MK-2206",
                "ipataserib",
                "everolimus",
                "temsirolimus"
            ]
        }
    ]
}